236 related articles for article (PubMed ID: 10806906)
1. [Use of angiotensin II receptor blockaders in heart failure].
Bonarjee VV; Dickstein K
Tidsskr Nor Laegeforen; 2000 Mar; 120(7):817-21. PubMed ID: 10806906
[TBL] [Abstract][Full Text] [Related]
2. Angiotensin II receptor antagonists and heart failure: angiotensin-converting-enzyme inhibitors remain the first-line option.
Prescrire Int; 2005 Oct; 14(79):180-6. PubMed ID: 16285075
[TBL] [Abstract][Full Text] [Related]
3. [Dosage equivalents of AT1-receptor antagonists available in Germany].
Dominiak P; Häuser W
Dtsch Med Wochenschr; 2003 Oct; 128(44):2315-8. PubMed ID: 14593575
[No Abstract] [Full Text] [Related]
4. [Review of randomized trials of angiotensin receptor blockers in the treatment of patients with congestive heart failure].
Rakugi H; Ogihara T
Nihon Rinsho; 2001 Oct; 59(10):2051-61. PubMed ID: 11676153
[TBL] [Abstract][Full Text] [Related]
5. [ACE inhibitors or AT1 receptor antagonists?].
Riegger GA
Dtsch Med Wochenschr; 1999 Sep; 124 Suppl 2():S37-9. PubMed ID: 10535045
[No Abstract] [Full Text] [Related]
6. Effects of valsartan on morbidity and mortality in patients with heart failure not receiving angiotensin-converting enzyme inhibitors.
Maggioni AP; Anand I; Gottlieb SO; Latini R; Tognoni G; Cohn JN;
J Am Coll Cardiol; 2002 Oct; 40(8):1414-21. PubMed ID: 12392830
[TBL] [Abstract][Full Text] [Related]
7. [Angiotensin I receptor blockers for heart failure].
Fruhwald FM; Kickenweiz E; Zweiker R; Klein W
Wien Med Wochenschr; 2001; 151(7-8):157-9. PubMed ID: 11450163
[TBL] [Abstract][Full Text] [Related]
8. Maximally recommended doses of angiotensin-converting enzyme (ACE) inhibitors do not completely prevent ACE-mediated formation of angiotensin II in chronic heart failure.
Jorde UP; Ennezat PV; Lisker J; Suryadevara V; Infeld J; Cukon S; Hammer A; Sonnenblick EH; Le Jemtel TH
Circulation; 2000 Feb; 101(8):844-6. PubMed ID: 10694521
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetic-pharmacodynamic profile of angiotensin II receptor antagonists.
Csajka C; Buclin T; Brunner HR; Biollaz J
Clin Pharmacokinet; 1997 Jan; 32(1):1-29. PubMed ID: 9012554
[TBL] [Abstract][Full Text] [Related]
10. Valsartan in chronic heart failure.
Ripley TL
Ann Pharmacother; 2005 Mar; 39(3):460-9. PubMed ID: 15687480
[TBL] [Abstract][Full Text] [Related]
11. [Clinical study of the month. Effects of valsartan in chronic heart failure: the VAL-HeFT study].
Piérard L
Rev Med Liege; 2002 Jan; 57(1):57-9. PubMed ID: 11899501
[TBL] [Abstract][Full Text] [Related]
12. Enhancing cardiac protection after myocardial infarction: rationale for newer clinical trials of angiotensin receptor blockers.
Pfeffer MA
Am Heart J; 2000 Jan; 139(1 Pt 2):S23-8. PubMed ID: 10618584
[TBL] [Abstract][Full Text] [Related]
13. Angiotensin-II receptor antagonists: their place in therapy.
Kirk JK
Am Fam Physician; 1999 Jun; 59(11):3140-8. PubMed ID: 10392595
[TBL] [Abstract][Full Text] [Related]
14. A review of the current evidence for the use of angiotensin-receptor blockers in chronic heart failure.
Erhardt LR
Int J Clin Pract; 2005 May; 59(5):571-8. PubMed ID: 15857354
[TBL] [Abstract][Full Text] [Related]
15. The effect of valsartan, captopril, or both on atherosclerotic events after acute myocardial infarction: an analysis of the Valsartan in Acute Myocardial Infarction Trial (VALIANT).
McMurray J; Solomon S; Pieper K; Reed S; Rouleau J; Velazquez E; White H; Howlett J; Swedberg K; Maggioni A; Køber L; Van de Werf F; Califf R; Pfeffer M
J Am Coll Cardiol; 2006 Feb; 47(4):726-33. PubMed ID: 16487836
[TBL] [Abstract][Full Text] [Related]
16. [AT 1-blocker can be given in addition to ACE inhibitor and beta blocker. "Triple therapy decidedly well tolerated even in severe heart failure"].
Dietz R
MMW Fortschr Med; 2004 May; 146(22):50. PubMed ID: 15373115
[No Abstract] [Full Text] [Related]
17. Comparative angiotensin II receptor blockade in healthy volunteers: the importance of dosing.
Maillard MP; Würzner G; Nussberger J; Centeno C; Burnier M; Brunner HR
Clin Pharmacol Ther; 2002 Jan; 71(1):68-76. PubMed ID: 11823759
[TBL] [Abstract][Full Text] [Related]
18. Angiotensin II receptor antagonists in heart failure: rationale and design of the evaluation of losartan in the elderly (ELITE) trial.
Pitt B; Chang P; Timmermans PB
Cardiovasc Drugs Ther; 1995 Oct; 9(5):693-700. PubMed ID: 8573552
[TBL] [Abstract][Full Text] [Related]
19. [Pharmocological therapeutics for chronic heart failure--how to use ARB (angiotensin receptor blocker].
Kudo Y; Komuro I; Akazawa H
Nihon Rinsho; 2007 May; 65 Suppl 5():84-9. PubMed ID: 17571370
[No Abstract] [Full Text] [Related]
20. New competition in the realm of renin-angiotensin axis inhibition; the angiotensin II receptor antagonists in congestive heart failure.
Martineau P; Goulet J
Ann Pharmacother; 2001 Jan; 35(1):71-84. PubMed ID: 11197588
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
